J Korean Ophthalmol Soc.  1996 Oct;37(10):1656-1662.

The Effect of Daunorubicin on Experimental Proliferative Vitreoretinopathy

Affiliations
  • 1Department of Ophthalmology, Kyung Hee University, Seoul, Korea.

Abstract

Proliferative vitreoretinopathy (PVR) is a main cause of failure in retinal reattachment surgery. There have been many studies about the inhibition of proliferative vitreoretinophthy with several drugs. Authors investigated the inhibitory effect of proliferative vitreoretinopathy and retinal toxicity with various concentration of daunorubicin after intravitreal injection into the eyes of the pigmented rabbit. 7 pigment rabbit (11eyes) were used as subjects. After lensectomy and vitrectomy, control group was injected dermal fibroblast and F-BSS, and treatment group was injected dermal fibroblast and 5, 10, 15, 30 nmol Daunorubicin. At two weeks after intravitreal injection, both group were enucleated and examined with gross finding, light--microscopy, and electronmicroscopy. In all control group, proliferative vitreoretinopathy was found, but only preretinal membrane formation was found in 5, 10 nmol Daunorubicin injected group. In 15 nmol Daunorubicin injected group, the retina structure was preserved normally. In 30 nmol Daunorubicin injected group, the retinal outer segment was degenerated in microscopic finding. These results show that Daunorubicin has a potent effect on proliferative vitreoretinopathy, especially in 15 nmol, but retinal toxicity is suspected in marethan 30 nmol.

Keyword

Proliferative vitreoretinopathy (PVR); Daunorubicin; Dermal fibroblast; Vitrectomy; Intravitreal injection

MeSH Terms

Daunorubicin*
Fibroblasts
Intravitreal Injections
Membranes
Retina
Retinal Photoreceptor Cell Outer Segment
Retinaldehyde
Vitrectomy
Vitreoretinopathy, Proliferative*
Daunorubicin
Retinaldehyde
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr